how many square feet are leased by alexion pharmaceuticals , inc?
item 2 . properties . we conduct our primary operations at the owned and leased facilities described below . location operations conducted approximate square feet expiration new haven , connecticut corporate headquarters and executive , sales , research and development offices 514000 .

| Location | Operations Conducted | ApproximateSquare Feet | LeaseExpirationDates |
| :--- | :--- | :--- | :--- |
| New Haven, Connecticut | Corporate headquarters and executive, sales, research and development offices | 514,000 | 2030 |
| Dublin, Ireland | Global supply chain, distribution, and administration offices | 215,000 | Owned |
| Lexington, Massachusetts | Research and development offices | 81,000 | 2019 |
| Bogart, Georgia | Commercial, research and development manufacturing | 70,000 | 2024 |
| Smithfield, Rhode Island | Commercial, research and development manufacturing | 67,000 | Owned |
| Zurich, Switzerland | Regional executive and sales offices | 69,000 | 2025 |

we believe that our administrative office space is adequate to meet our needs for the foreseeable future . we also believe that our research and development facilities and our manufacturing facility , together with third party manufacturing facilities , will be adequate for our on-going activities . in addition to the locations above , we also lease space in other u.s . locations and in foreign countries to support our operations as a global organization . as of december 31 , 2015 , we also leased approximately 254000 square feet in cheshire , connecticut , which was the previous location of our corporate headquarters and executive , sales , research and development offices . in december 2015 , we entered into an early termination of this lease and will occupy this space through may 2016 . in april 2014 , we purchased a fill/finish facility in athlone , ireland . following refurbishment of the facility , and after successful completion of the appropriate validation processes and regulatory approvals , the facility will become our first company-owned fill/finish and packaging facility for our commercial and clinical products . in may 2015 , we announced plans to construct a new biologics manufacturing facility on our existing property in dublin ireland , which is expected to be completed by 2020 . item 3 . legal proceedings . in may 2015 , we received a subpoena in connection with an investigation by the enforcement division of the sec requesting information related to our grant-making activities and compliance with the fcpa in various countries . the sec also seeks information related to alexion 2019s recalls of specific lots of soliris and related securities disclosures . in addition , in october 2015 , alexion received a request from the doj for the voluntary production of documents and other information pertaining to alexion's compliance with the fcpa . alexion is cooperating with these investigations . at this time , alexion is unable to predict the duration , scope or outcome of these investigations . given the ongoing nature of these investigations , management does not currently believe a loss related to these matters is probable or that the potential magnitude of such loss or range of loss , if any , can be reasonably estimated . item 4 . mine safety disclosures . not applicable. .

alexion_square_feet = 514000 + 81000
total_square_feet = alexion_square_feet + 70000 + 69000
answer = total_square_feet